| Outcome Measures: |
Primary: Number (incidence) of adverse events (AEs), Measured as count of events., From baseline (week 0) to 26 weeks | Secondary: Number (incidence) of hypoglycaemia level 3 or level 2 according to American Diabetes Association (ADA) guideline 2020, Measured as count of events. Level 2 refers to glucose less than (\<) 54 milligrams per deciliter (mg/dL) (3.0 millimoles per liter \[mmol/L\]). Level 3 refers to a severe event characterized by altered mental and/or physical status requiring assistance for treatment of hypoglycaemia., From baseline (week 0) to 26 weeks|Change in glycated haemoglobin (HbA1c), Measured in percentage., From baseline (week 0) to 26 weeks|Participants achieving HbA1c target < 7.0 percent (%), Measured as count of participants., At 26 weeks|Change in fasting blood glucose (FBG)/fasting plasma glucose (FPG), Measured in milligrams per deciliter (mg/dl)., From baseline (week 0) to 26 weeks|Change in post prandial blood glucose (PPBG)/post prandial plasma glucose (PPPG), Measured in mg/dl., From baseline (week 0) to 26 weeks|Change in body weight, Measured in kilogram (kg)., From baseline (week 0) to 26 weeks|Dose of Ozempic, Measured in milligrams per day (mg/day)., At 26 weeks
|
